Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients, helping to maintain adequate cerebral blood flow after bleeding in the brain.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to stringent quality standards and reliable sourcing for healthcare institutions.

Nimodipine acts on the cerebrovascular system to reduce the risk of vasospasm after bleeding in the brain. - Prevention of cerebral vasospasm after subarachnoid hemorrhage: lowers the incidence of delayed ischemic neurological deficits. - Management of aneurysmal subarachnoid hemorrhage: supports cerebral perfusion during the acute phase. - Delayed cerebral ischemia following subarachnoid hemorrhage: helps maintain adequate blood flow to vulnerable brain tissue.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional upset stomach. - Flushing: warmth and redness of the skin. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or swelling. - Stevens‑Johnson syndrome: severe skin reaction. - Seizures: uncommon neurologic event.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Monitor blood pressure: watch for symptomatic hypotension. - Assess hepatic function: adjust use if liver impairment is present. - Avoid abrupt discontinuation: sudden stop may precipitate rebound vasospasm. - Use with caution in the elderly: increased sensitivity to hemodynamic changes. - Store at room temperature: keep in the original pack, protect from moisture.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Concurrent calcium channel blockers: additive hypotensive effect. - Nitrates: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Beta‑blockers: monitor for bradycardia. - Diuretics: watch electrolyte balance and blood pressure.